HENLIUS (02696) surged over 8% intraday, closing up 5.34% at HK$77.95 with a turnover of HK$90.26 million as of press time.

On the news front, HENLIUS announced that it recently completed the first patient dosing in the United States for its international multicenter Phase 2 clinical study of HLX43 injection (a PD-L1 antibody-drug conjugate targeting advanced non-small cell lung cancer (NSCLC) patients). CMB International issued a research report stating that as HENLIUS's biosimilars continue to generate cash flows in China and globally, the group is evolving into an innovative biologics company led by HLX43.

Notably, the official website of the 2025 World Conference on Lung Cancer (WCLC) recently announced selected abstracts, with HENLIUS successfully having 10 lung cancer research studies selected. The selected studies focus on three core innovative drugs: the anti-PD-1 monoclonal antibody serplulimab, the anti-EGFR monoclonal antibody HLX07, and HLX43, the world's first PD-L1 ADC to enter Phase 2 clinical trials.

Citi indicated that HENLIUS is set to release the latest data on HLX43 at WCLC, which will further reveal its potential in non-small cell lung cancer (NSCLC) treatment. If HLX43 can maintain an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in more diverse samples, such data would be highly compelling.